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The interaction of human red blood cells carrying antihuman collagen antibody with collagen-coated 
surfaces was studied. Avidin was used as bifunctional crosslinking agent for the attachment of antibody 
to the red blood cell surface. Antibody-carrying red blood cells efficiently and specifically bound to 
collagen-coated surface covering a significant part of the surface. The components of normal blood had 
an insignificant effect on red blood cell binding. A model of drug targeting to the injured sites(s) of blood 
vessel wall is proposed. 
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1. INTRODUCTION 
The problem of drug targeting is attracting in- 
creasing attention [l-3]. The major principle of 
targeting consists in attachment of a drug or drug 
container to a compound able to bind specifically 
to some part of organ or tissue. Antibodies, hor- 
mones and lectins can serve as such compounds. 
Thus, the drug should be concentrated at the target 
site and not be evenly distributed over the 
organism. Advantages of this approach include: 
(i) The possibility to reduce side effects of a drug; 
(ii) Decrease of the total dose which is especially 
important when drugs are expensive and not 
easily available. 
At present two systems of targeting are being 
most intensively developed: 
(i) That using ‘immunotoxins’ [2], which repre- 
sent the catalytic subunit of natural toxin (e.g., 
ricin, diphtheria, toxin) attached to an an- 
tibody of defined specificity. Immunotoxins 
are supposed to be mainly used for cancer 
treatment. 
vantage of this system includes insulation of a 
drug from the surrounding medium; being in- 
side a liposome, a drug does not cause side ef- 
fects and is not destructed itself. 
It is clear that not only liposomes can be used as 
a container: the use of red blood cells and their 
ghosts seems rather promising. Red cells of dif- 
ferent origin can be ‘loaded’ by both high 
molecular mass and low molecular mass com- 
pounds and reinjected into bloodstream [4-71 
These red blood cells circulate for a longer time 
(half-time of clearance is equal to several days 
[4-71) than liposomes, which can be removed from 
bloodstream within several hours [8]. It can be 
assumed that if red blood cells are loaded with a 
drug, and antibodies are attached to their surface, 
then such red cells will circulate in the organism 
delivering their content to the target. 
(ii) That using liposomes: Antibodies and other 
specific proteins are attached (covalently or 
non-covalently) to the external surface of 
liposomes [3]. Here, a liposome serves as a 
‘container’ for a drug, and an additional ad- 
Here, we investigated some properties of our 
model system; first of all, specificity. We used 
human red blood cells with anti-human collagen 
antibody attached to their surface. Collagen- 
coated plastic surfaces were used as a target. Our 
system simulated transport of drugs entrapped into 
red blood cells to a denuded area of blood vessel. 
This model was chosen [9] as endothelial injury of 
blood vessel wall with subsequent exposure of sub- 
endothelial components, including collagen, could 
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be one of the key mechanisms of thrombogenesis, 
and probably, atherogenesis (review [lo-121). 
When targeting of biologically active compounds 
into these areas is mastered it will be possible to in- 
terfere with the processes occurring there, and, to 
some extent, control them. 
2. MATERIALS AND METHODS 
Blood of healthy volunteers was collected into 
acid citrate anticoagulant and kept at 4°C. Before 
use, red blood cells were washed 5 times by cen- 
trifugation with phosphate-buffered solution 
(PBS) (138 mM NaCl, 2.7 mM KCI, 8.1 mM 
Na2HP04, 1.5 mM KH2P04, pH 7.4). 
Type I bovine collagen and rabbit anti-collagen 
antibody were obtained as in [9]. Type I and III 
collagens from human placenta and corresponding 
rabbit antibodies were obtained according to [13]. 
Type IV and V collagens from human placenta 
were isolated as in [14]. Avidin was isolated from 
hen egg white as in [15] (crystallization step omit- 
ted). Avidin specific activity determined spectro- 
photometrically by spectral shift method [16] was 
equal to 14- 15 units/mg. N-Hydroxysuccinimide 
ester of biotin was synthesized according to [ 171. 
Purity of the preparation was tested by thin-layer 
chromatography on silica-gel (Merck) in chloro- 
form-methanol system (9 : 1, v/v). Human plasma 
fibronectin was kindly donated by V.E. 
Koteliansky. 
2.1 Coating of plastic by collagen 
Collagen solution (1 ml, 20pg/ml) in 0.02 M 
bicarbonate buffer (pH 9.6) was added into each 
well of Falcon Multiwell 3008 and incubated for 
2 h at 37°C and overnight at 4°C. Then the well 
was washed and incubated for 2 h with PBS con- 
taining 4 mg bovine serum albumin/ml (Sigma). 
2.2. Attachment of antibodies to red blood cells 
Red blood cells were washed by 5 x 10 ml PBS. 
Then 0.1 ml 0.1 M borate buffer (pH 9.2) and 3 ~1 
0.1 M solution of biotin N-hydroxysuccinimide 
ester in dimethylformamide were added into 1 ml 
red blood cell suspension in PBS (hematocrit value 
10%). Reaction mixture was incubated at room 
temperature for 20 min, then red cells were washed 
by centrifugation by 5 x 10 ml PBS. 1 ml suspen- 
sion of modified red blood cells (hematocrit value 
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10%) was added to 1 ml avidin solution, 1 mg/ml 
in PBS, and incubated with agitation for 1 h at 
4°C. Red blood cells were washed off non-bound 
avidin by 3 x 10 ml PBS. 
Biotin N-hydroxysuccinimide (0.1 M) in dime- 
thylformamide was added to 0.2-1.0 ml antibody 
rabbit non-immune Igci . PBS 
:;.3-I.0 mg/ml) to 0.3 mM final conch and in- 
cubated for 1 h at 4°C. The reaction mixture was 
dialyzed overnight at 4°C against 5 1 PBS. 
Modified protein solution (15 pl) was added to 
1 ml suspension of red blood cells coated by avidin 
(hematocrit value lo%), and incubated for 1 h 
with agitation at 4°C. Red blood cells were washed 
off non-bound protein by centrifugation by 
3 x 10 ml PBS. In experiments on quantitative 
determination of protein binding to the red blood 
cells 12SI-labelled rabbit IgG was added into initial 
protein solution as tracer. 
2.3. Incubation of red blood cells in collagen- 
coated wells 
Red blood cell suspension (250~1, 4 x 10’ 
cells/ml) was added into each collagen-coated well 
and incubated for 1 h at room temperature with 
occasional strirring or permanent rotation around 
a horizontal axis (Fisher Roto-Rack, Model 343, 
15 rev./min). Then wells were washed with 
4 x 1 ml PBS with rotation (for 5 min each time). 
Bound red blood cells were fixed by 1 ml 0.5% 
glutaraldehyde in PBS overnight at 4°C and wash- 
ed with water. The amount of bound red blood 
cells was determined by microscopic counting in 
6C-2 profile projector (Nikon) with 400 x 
objective. 
3. RESULTS AND DISCUSSION 
For attachment of antibodies to red blood cell 
surface we used avidin-biotin non-covalent inter- 
action. Avidin has 4 biotin-binding sites and can 
serve as bifunctional cross-linking agent for 
molecules carrying biotin groups [18,19]. The 
scheme of antibody attachment is shown in fig. 1. 
At first, red blood cells and antibody were 
separately treated by biotin N-hydroxysuccinimide 
ester which resulted in the appearance of biotin 
groups on red blood cell surface and in antibody 
molecule. By titration with trinitrobenzene 
sulfonic acid [21] it was found that this treatment 
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Fig. 1, Scheme of antibody attachment to red blood cell 
surface. Abbreviations: RBC, red blood cells; B, biotin; 
BOSu, biotin N-hydroxysuccinimide ester; Av, avidin; 
Ab, antibody. 
led to modification of 15% amino groups of anti- 
body molecule. According to the data obtained by 
enzyme-Iinked immunosorbe~t assay this modifi- 
cation does not decrease antibody activity. Red 
blood cells were then incubated in avidin solution, 
non-bound avidin was removed and biotin-modi- 
fied antibody was added. As a result, antibodies 
attached to the red blood cell surface through 
avidin molecule. Besides, in this case avidin serves 
as a spacer arm 55 A in length [19]. Since 
avidin-biotin interaction is non-covalent, it is very 
rapid (kass = 7 x IO’ M-i.s-‘), and attachment 
does not require proIonged incubations. This in- 
teraCtiOn iS afso very strong (f& = 1.2 X Io-‘5 M 
$IQl) and the half-time avidin-biotin complex 
dissociation is 200 days [IQ]. Due to these 
peculiarities the method of attachment is very effi- 
cient. For example, adding only 5 fig biotin-modi- 
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106/well 
Fig. 2. Dependence of red blood cell binding on their 
concentration, Red blood cells carrying antibady were 
incubated in wells coated with type I human collagen in 
section 2. 
fied antibody to 2 x IO’ red blood cells it is possi- 
bfe to attach 30% of added antibody within 1 h, 
which is practicaffy impossible for methods of 
covalent attachment. In this case 30 000 antibody 
molecules attach/red blood cell. In a typical ex- 
periment 100 ~8 antibody were usually added per 
lo9 red blood cells providing 80 000-100 000 anti- 
body molecules attached per red blood cell’with an 
attachment efficiency of -25%. 
Incubation of antibody-carrying red blood cells 
in collagen-coated wells led to the binding of 
erythrocytes to the cohagen-coated surface, This 
binding depends on red bfood ceell concentration 
and reaches 3.6 x to6 red blood cefls/weil with a 
surface area of 2 cm’ (fig. 2)*. Binding of red 
blood cells carrying non-immune IgG is equal to 
4-8 x IO3 cells/well (not shown in fig. 2 due to a 
discrepancy of scale). Thus, attachment of an- 
tibody to red blood cells instead of non-immune 
IgG leads to the increase of red blood cells binding 
to collagen by 400-800 times. The same results 
were obtained when type I bovine collagen and 
corresponding rabbit antibodies were used (not 
shown). 
* These results were obtained using collagen absorbed at 
the well surface. Similar results were obtained with the 
wells coated by fibrillar collagen, as in [9], 
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From fig. 2 one can calculate that at maximal 
binding the surface area occupied by one red blood 
cell is ==70pm’. Since human red blood cell 
represents a disc of 8 pm diam., the area occupied 
by a flatly lying red blood cell is =50pm2. Thus, 
in our experiments bound cells occupy -70% of 
available surface. 
Specificity of red blood cell binding to collagen 
was also tested in experiments with blocking of col- 
lagen antigenic determinants. Far this purpose, 
collagen in wells was preincubated with different 
amounts of anti-collagen antibody. As the amount 
of antibody added into a well increases, red blood 
cell binding decreases (fig. 3); at > 1Opg anti- 
body/well, binding is pra~ti~ly absent (fig. 3). 
These results confirm that red blood cell binding 
strictly depends on the interaction of antibody with 
collagen antigenic determinants. 
Specificity of red blood cell binding according to 
the type of protein attached to the plastic surface 
I I 
z 
3: 4 t I 
5 Ii? 15 
ANTIl3ODY ADDED, jug/well 
Fig. 3. Effect of coIlagen preincubation with antibody 
on red cell binding. In wells coated with type I human 
collagen the indicated amounts of antibody to this col- 
lagen were added in 0.5 ml PBS containing 4 mg/ml 
bovine serum albumin and incubated for 1 h at room 
temperature.Then the wells were washed by 3 x 1 ml 
PBS with bovine serum albumin. Red blood cell incuba- 
tion, fixation and counting of bound red cells were per- 
formed as in section 2. 
Table 1 
Binding of antibody-c~rying red blood cells to the sur- 
faces coated with different types of collagen 
Coffagen type Red blood celb bound 
(lO~/weil~ 
I 3.4 
III -Co.01 
IV <O.Ol 
V <O.Ol 
Wells were coated with human collagen of different 
types as in section 2. PBS (250~1) containing 107 red 
blood cells carrying antibody to type I human collagen 
were added into each well. Incubation, fixation and 
counting of bound red cells were performed as in section 
2. Binding of red blood cefls carrying non-immune 
globulin was < IO4 cellsiwell in a11 cases. 
was tested by coating wells with human collagen of 
different types. Table 1 demonstrates that binding 
of red blood cells carrying antibody to type I col- 
lagen occurs only on type I collagen. Binding is 
practically absent with collagens of types III-V. 
We also tested the effect of some components of 
human normal blood on red blood cell binding to 
collagen. For instance, such collagen-binding pro- 
tein as fibronectin did not affect the binding up to 
its physiological con~entrations~ i.e., up to 
0.3 mg/ml [20f. This can be accounted for by the 
suggestion that fibronectin-binding sites of col- 
lagen are insignificantly overlapped with most of 
its antigenic determinants. Other blood proteins 
also did not affect red blood cell interaction with 
collagen, since addition of human blood plasma to 
< 50% (v/v) did not change the binding (not 
shown). 
To study the influence of cellular blood com- 
ponents on red blood cell binding we added dif- 
ferent amounts of intact er~hro~~es into incuba- 
tion mixture. This addition led to the inhibition of 
antibody-carrying red blood cell binding (fig, 4). 
At concentrations of intact erythrocytes cor- 
responding to physiological hematocrit values 
(50%), inhibition was 60%. Thus, presence of > 
lOO-fold excess of intact red blood cells decreased 
binding by 2.5-fold. Evidently, inhibition is due to 
the blocking of the available surface and, most 
probably, it can be overcome by increase of in- 
cubation time and intensity of agitation. This is 
confirmed by the fact that if continuous agitation 
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2.5 5‘0 
UNMODtFtED RED BLOOD CELL 
CONCENTRATtON, 10Q/ml 
Fig. 4. Effect of intact red blood cells on the binding of 
anti~~dy”~arrying red blood cells. 107 red blood celfs 
carrying antibodies to type I collagen and different 
amounts of intact red blood cells were added into each 
we11 coated with human collagen. The total volume in 
the well is 250& Incubation, fixation and counting of 
bound red blood ceils were performed as in section 2. 
is replaced by occasional agitation, the degree of 
inhibition increases up to 90% at 5 x 10’ intact red 
blood cells/ml. 
We have demonstrated the possibility af target- 
ing of red blood ceils carrying antibody to surfaces 
coated with antigen, particularly with human col- 
lagen. In this case, red blood cell binding is highly 
effective and specific, and the effect of blood com- 
ponents is either absent or expressed rather weak- 
ly. It is not possible to apply the results obtained 
directly to the case of denuded vessef in vivo: 
(9 
(ii) 
(iii) 
Coftagen of blood vessel wah can be Iinked 
with other structural components (e.g., pro- 
teins, proteoglycans), which can mask its anti- 
genie determinants; 
Unevenness of microrelief of denuded vessel 
wah can be comparable to erythrocyte size 
which will sterically prevent the contact of 
antibodies with collagen at red blood cell 
surface; 
We did not study the effect of platelets which 
very actively interact with collagen. 
Ah these questions shouid be tested ex~rim~ntal~y 
on the denuded vessel. 
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